The latest price target for Tango Therapeutics (NASDAQ:TNGX) was reported by Cantor Fitzgerald on December 5, 2024. The analyst firm set a price target for $0.00 expecting TNGX to fall to within 12 months (a possible -100.00% downside). 18 analyst firms have reported ratings in the last year.

The latest analyst rating for Tango Therapeutics (NASDAQ:TNGX) was provided by Cantor Fitzgerald, and Tango Therapeutics reiterated their overweight rating.

There is no last upgrade for Tango Therapeutics

There is no last downgrade for Tango Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Tango Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Tango Therapeutics was filed on December 5, 2024 so you should expect the next rating to be made available sometime around December 5, 2025.

While ratings are subjective and will change, the latest Tango Therapeutics (TNGX) rating was a reiterated with a price target of $0.00 to $0.00. The current price Tango Therapeutics (TNGX) is trading at is $3.12, which is out of the analyst’s predicted range.